Oncotarget · 2017 · 56 citations · 50 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologyTumor ProgressionCancer Cell SignalingCancer ProgressionCancer Stem Cell BiologyCancer Stem CellsMalignant NeoplasmsOvarian CancerCancer Stem Cell ProliferationCancer Stem Cell Signaling PathwaysCancer Stem Cell TargetingCancer Stem-like CellsMalignant Ovarian TumorsMetastatic Cancer Stem CellsOvarian Cancer MetastasisOvarian Cancer Pathogenesis
// Sham S. Kakar 1, 2 , Seema Parte 2 , Kelsey Carter 1 , Irving G. Joshua 1 , Christopher Worth 2 , Pranela Rameshwar 3 and Mariusz Z. Ratajczak 4 1 Department of Physiology, University of Louisville, Louisville, KY 40202, USA 2 James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA 3 Department of Medicine, Hematology/Oncology, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA 4 Department of Medicine, University of Louisville, Louisville, KY 40202, USA Correspondence to: Sham S. Kakar, email: sskaka01@louisville.edu Keywords: cancer stem cells, ALDH1, ovarian cancer, withaferin A, securin Received: May 09, 2017     Accepted: June 26, 2017     Published: August 10, 2017 ABSTRACT Ovarian cancer is the fifth leading cause of deaths due to cancer among women in the United States. In 2017, 22,440 women are expected to be diagnosed with ovarian cancer and 14,080 women will die with it. Currently used chemotherapies (Cisplatin or platinum/taxane combination) targets cancer cells, but spares cancer stem cells (CSCs), which are responsible for tumor relapse leading to recurrence of cancer. Aldehyde dehydrogenase I (ALDH1) positive cancer stem cells are one of the major populations in ovarian tumor and have been related to tumor progression and metastasis. In our studies, we observed expression of ALDH1 in both ovarian surface epithelium (OSE) and cortex with high levels of expression in OSE in normal ovary and benign (BN) tumor, compared to borderline (BL) and high grade (HG) ovarian tumors. In contrast, high levels of expression of ALDH1 were observed in cortex in BL and HG tumors compared to normal ovary and BN tumor. Withaferin A (WFA) alone or in combination with cisplatin (CIS) significantly inhibited the spheroid formation (tumorigenic potential) of isolated ALDH1 CSCs in vitro and significantly reduced its expression in tumors collected from mice bearing orthotopic ovarian tumor compared to control. Treatment of animals with CIS alone significantly increased the ALDH1 CSC population in tumors, suggesting that CIS targets cancer cells but spares cancer stem cells, which undergo amplification. WFA and CIS combination suppresses the expression of securin an “oncogene”, suggesting that securin may serve as a downstream signaling gene to mediate the antitumor effects of WFA.
50
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Prospective identification of tumorigenic breast cancer cells
Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text
Medicine, Cell Biology, Oncology +11
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +11
Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer et al. · Journal of Clinical Oncology · 2003 · 2.1K citations
Medicine, Gynecology, Oncology +17